SCHEMBL23330869

SCHEMBL23330869

COc1ccc(C(=O)Nc2cnc(Cl)nc2NN)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NNMT P40261 2/20 0.47
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
AHR P35869 1/20 0.44
MKNK1 Q9BUB5 1/20 0.43
MKNK2 Q9HBH9 1/20 0.43
GPR35 Q9HC97 1/20 0.42
GPR55 Q9Y2T6 1/20 0.42
HDAC1 Q13547 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
PTPN1 P18031 1/20 0.40
P4HTM Q9NXG6 1/20 0.40
P2RX3 P56373 1/20 0.39
RORC P51449 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 1/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
ALDH1A1 P00352 2/20 0.38
HTT P42858 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23330538 0.86 F10 (0.51) MEN1KMT2AHDAC1SMN1; SMN2KDM4E
SCHEMBL23330872 0.85 MEN1 (0.48) NNMTMEN1KMT2AAHRMKNK1
SCHEMBL23331033 0.79 KCNQ3 (0.47) MEN1KMT2AHDAC1P4HTMHPGD
SCHEMBL23330838 0.78 KCNMA1 (0.47) KMT2AHDAC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL23330680 0.78 ADORA3 (0.45) MEN1KMT2AKDM4EALDH1A1NPC1
SCHEMBL23330652 0.77 HDAC1 (0.53) HDAC1SMN1; SMN2MAPTALDH1A1HTT
SCHEMBL23331251 0.74 PTK2 (0.39) KDM4EHSD17B10
SCHEMBL1882423 0.74 NNMT (0.67) NNMTMEN1KMT2AMKNK1MKNK2
SCHEMBL23330835 0.73 BRAF (0.36) SMN1; SMN2P2RX3MAPTHPGDNPC1
SCHEMBL23330675 0.73 ALDH1A1 (0.44) KMT2ASMN1; SMN2KDM4EALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230028221-A1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) 2023-01-26 US disclosed
WO-2021083380-A1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海科技大学 2021-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230028221-A1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF CYP4F11, CYP4A11, HSD11B1 NNMT 1636/4885MEN1 954/4885KMT2A 3987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.